16284058

Source:http://linkedlifedata.com/resource/pubmed/id/16284058

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006826, umls-concept:C0019994, umls-concept:C0030705, umls-concept:C0146224, umls-concept:C0205179, umls-concept:C0205195, umls-concept:C0205208, umls-concept:C0205390, umls-concept:C0920321, umls-concept:C0950721, umls-concept:C1513822, umls-concept:C1880171, umls-concept:C2603343
pubmed:issue	2
pubmed:dateCreated	2006-1-23
pubmed:abstractText	7-Hydroxystaurosporine (UCN-01) inhibits serine-threonine kinases including the Ca2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4, 6, Chk-1 and PDK1. UCN-01 mediates distinct effects in vitro/in vivo: cell cycle arrest in G1, abrogation of G2 arrest by inhibiting chk1, induction of apoptosis and potentiation of cytotoxicity of S-phase-active chemotherapeutics including the topoisomerase 1 inhibitor topotecan (T). This phase I study was designed to determine the maximal tolerated dose (MTD), recommended phase 2 dose (RPTD), toxicity profile, pharmacokinetics and antitumor activity of T and UCN-01 in patients with refractory solid tumors.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/N01-CM-1701
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/7-hydroxystaurosporine, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Staurosporine, http://linkedlifedata.com/resource/pubmed/chemical/Topotecan
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0923-7534
pubmed:author	pubmed-author:BrownSS, pubmed-author:ChenE XEX, pubmed-author:CoT GTG, pubmed-author:DanceyJ EJE, pubmed-author:HirthH PHP, pubmed-author:HotteS JSJ, pubmed-author:MooreMM, pubmed-author:PondG RGR, pubmed-author:WinquistE WEW
pubmed:issnType	Print
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	334-40
pubmed:dateRevised	2007-12-3
pubmed:meshHeading	pubmed-meshheading:16284058-Adult, pubmed-meshheading:16284058-Aged, pubmed-meshheading:16284058-Antineoplastic Agents, pubmed-meshheading:16284058-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16284058-Colonic Neoplasms, pubmed-meshheading:16284058-Dose-Response Relationship, Drug, pubmed-meshheading:16284058-Female, pubmed-meshheading:16284058-Humans, pubmed-meshheading:16284058-Infusions, Intravenous, pubmed-meshheading:16284058-Leukopenia, pubmed-meshheading:16284058-Male, pubmed-meshheading:16284058-Middle Aged, pubmed-meshheading:16284058-Neutropenia, pubmed-meshheading:16284058-Ovarian Neoplasms, pubmed-meshheading:16284058-Salivary Gland Neoplasms, pubmed-meshheading:16284058-Staurosporine, pubmed-meshheading:16284058-Survival Analysis, pubmed-meshheading:16284058-Topotecan
pubmed:year	2006
pubmed:articleTitle	Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
pubmed:affiliation	Princess Margaret Hospital Phase II Consortium, Cancer Therapy Evaluation Program, and National Cancer Institute, Bethesda, MD, USA. sebastien.hotte@hrcc.on.ca
pubmed:publicationType	Journal Article, Clinical Trial, Clinical Trial, Phase I, Research Support, N.I.H., Extramural